Pharmacoeconomic modelling in schizophrenia
Author
Abstract
Suggested Citation
DOI: 10.1007/s10198-005-0326-x
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- J.Robert Beck & Stephen G. Pauker, 1983. "The Markov Process in Medical Prognosis," Medical Decision Making, , vol. 3(4), pages 419-458, December.
- repec:spr:pharme:v:17:y:2000:i:6:p:545-553 is not listed on IDEAS
- repec:spr:pharme:v:15:y:1999:i:6:p:597-610 is not listed on IDEAS
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Rowan Iskandar, 2018. "A theoretical foundation for state-transition cohort models in health decision analysis," PLOS ONE, Public Library of Science, vol. 13(12), pages 1-11, December.
- Franck Maunoury & Christian Farinetto & Stéphane Ruckly & Jeremy Guenezan & Jean-Christophe Lucet & Alain Lepape & Julien Pascal & Bertrand Souweine & Olivier Mimoz & Jean-François Timsit, 2018. "Cost-effectiveness analysis of chlorhexidine-alcohol versus povidone iodine-alcohol solution in the prevention of intravascular-catheter-related bloodstream infections in France," PLOS ONE, Public Library of Science, vol. 13(5), pages 1-16, May.
- Paul J. Roach & Craig Fleming & Michael D. Hagen & Stephen G. Pauker, 1988. "Prostatic Cancer in a Patient with Asymptomatic HIV Infection," Medical Decision Making, , vol. 8(2), pages 132-144, June.
- Manouchehr Tavakoli & Neil Pumford & Mark Woodward & Alex Doney & John Chalmers & Stephen MacMahon & Ronald MacWalter, 2009. "An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 111-119, February.
- Steven M. Shechter & Matthew D. Bailey & Andrew J. Schaefer & Mark S. Roberts, 2008. "The Optimal Time to Initiate HIV Therapy Under Ordered Health States," Operations Research, INFORMS, vol. 56(1), pages 20-33, February.
- Aslam Anis & Huiying Sun & Sonia Singh & John Woolcott & Bohdan Nosyk & Marc Brisson, 2006. "A Cost-Utility Analysis of Losartan versus Atenolol in the Treatment of Hypertension with Left Ventricular Hypertrophy," PharmacoEconomics, Springer, vol. 24(4), pages 387-400, April.
- Dominique Bureau & Geneviève Plu-Bureau & Jean-Christophe Thalabard, 1993. "L'évaluation économique des traitements médicaux : méthodes et enjeux," Économie et Statistique, Programme National Persée, vol. 266(1), pages 65-75.
- Donna M. Edwards & Ross D. Shachter & Douglas K. Owens, 1998. "A Dynamic HIV-Transmission Model for Evaluating the Costs and Benefits of Vaccine Programs," Interfaces, INFORMS, vol. 28(3), pages 144-166, June.
- David G. Simon, 1986. "A Cost-effectiveness Analysis of Cyclosporine in Cadaveric Kidney Transplantation," Medical Decision Making, , vol. 6(4), pages 199-207, December.
- de Wit, G.Ardine & Ramsteijn, Paul G & de Charro, Frank Th, 1998. "Economic evaluation of end stage renal disease treatment," Health Policy, Elsevier, vol. 44(3), pages 215-232, June.
- Uwe Siebert & Gaby Sroczynski & Jürgen Wasem & Wolfgang Greiner & Ulrike Ravens-Sieberer & Pamela Aidelsburger & Bärbel Kurth & Monika Bullinger & J.-Matthias Schulenburg & John Wong & Siegbert Rossol, 2005. "Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(2), pages 112-123, June.
- Gerardo Machnicki & Jean-Francois Ricci & Daniel Brennan & Mark Schnitzler, 2008. "Economic Impact and Long-Term Graft Outcomes of Mycophenolate Mofetil Dosage Modifications Following Gastrointestinal Complications in Renal Transplant Recipients," PharmacoEconomics, Springer, vol. 26(11), pages 951-967, November.
- Craig Fleming & John B. Wong & Alan J. Moskowitz & Stephen G. Pauker, 1988. "A Peripartum Neurologic Event: Shooting from the Hip," Medical Decision Making, , vol. 8(1), pages 55-71, February.
- C. Kent Kwoh & J. Robert Beck & Stephen G. Pauker, 1984. "Repeated Syncope with Negative Diagnostic Evaluation," Medical Decision Making, , vol. 4(3), pages 351-377, August.
- Roy Lothan & Noa Gutman & Dan Yamin, 2022. "Country versus pharmaceutical company interests for hepatitis C treatment," Health Care Management Science, Springer, vol. 25(4), pages 725-749, December.
- Beate Jahn & Sarah Friedrich & Joachim Behnke & Joachim Engel & Ursula Garczarek & Ralf Münnich & Markus Pauly & Adalbert Wilhelm & Olaf Wolkenhauer & Markus Zwick & Uwe Siebert & Tim Friede, 2022. "On the role of data, statistics and decisions in a pandemic," AStA Advances in Statistical Analysis, Springer;German Statistical Society, vol. 106(3), pages 349-382, September.
- Visalakshi Jeyaseelan & Tunny Sebastian & Jeyaseelan Lakshmanan & Shrikant I Bangdiwala, 2016. "Longitudinal data analysis of mean passage time among malnutrition states: an application of Markov chains," Journal of Applied Statistics, Taylor & Francis Journals, vol. 43(15), pages 2729-2739, November.
- Felicitas Kuehne & Ursula Rochau & Noman Paracha & Jennifer M. Yeh & Eduardo Sabate & Uwe Siebert, 2022. "Estimating Treatment-Switching Bias in a Randomized Clinical Trial of Ovarian Cancer Treatment: Combining Causal Inference with Decision-Analytic Modeling," Medical Decision Making, , vol. 42(2), pages 194-207, February.
- Simon Frey & Roland Linder & Georg Juckel & Tom Stargardt, 2014. "Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(2), pages 133-142, March.
- Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
More about this item
Keywords
Atypical antipsychotic; Economic modelling; Schizophrenia; Cost-effectiveness analysis;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:7:y:2006:i:1:p:19-29. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.